Redeye raises its Base case of Xspray Pharma to SEK 200 (165) per share on the back of today’s successful bioequivalence study on healthy volunteers under fed conditions. Formal bioequivalence requirements for HyNap-Dasa were met, and we have increased the likelihood of approval to 90% (80%) and adjusted our timeline slightly.